Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal…
Sucampo Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
